Response Biomedical develops, manufactures and markets rapid on-site
diagnostic tests for use with its portable RAMP Platform for clinical and
environmental applications. RAMP represents a new paradigm in diagnostics that
provides high sensitivity and reliable information in minutes. It is ideally
suited to both point-of-care testing and laboratory use. The RAMP system
consists of a portable fluorescent reader and single-use disposable test
cartridges, and has the potential to be adapted to more than 250 medical and
non-medical tests currently performed in laboratories. RAMP clinical tests are
commercially available for the early detection of heart attack and congestive
heart failure.
In late 2006, the Company formed a strategic alliance with 3M Company to
commercialize rapid infectious disease tests. In the non-clinical market, RAMP
Tests are currently provided for the environmental detection of West Nile
Virus, and Biodefense applications including the rapid on-site detection of
anthrax, smallpox, ricin and botulinum toxin. Several other product
applications are under development. The Company has achieved CE Marking and
its Quality Management System is registered to ISO 13485: 2003 and ISO 9001:
2000.
Response Biomedical is a publicly traded company, listed on the TSX
Venture Exchange under the trading symbol "RBM" and quoted on the OTC Bulletin
Board under the symbol "RPBIF".
| Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing | 10/28/2008 - 07:00 | $5Million |
| Response Biomedical Announces $5.5 Million Financing | 10/14/2008 - 07:00 | $5Million |
| Response Biomedical Closes $12 Million Bought Deal Private Placement | 07/24/2007 - 20:17 | $12Million |
| Response Biomedical Announces $12 Million Bought Deal Private Placement | 07/10/2007 - 07:00 | $12Million |
| Response Biomedical Accepts Proposal to Undertake $10 Million Brokered Private Placement and Board Reorganization | 03/16/2006 - 08:00 | $10Million |
| Response Biomedical Undertakes $2 Million Private Placement | 12/15/2005 - 08:00 | $2Million |
| Response Biomedical Replaces Equity Private Placement With $1.58 Million Convertible Debentures | 10/25/2005 - 07:00 | $1Million |
| Response Biomedical Undertaking $2.5 Million Private Placement | 08/15/2005 - 07:00 | $2Million |